PEPCTN1812 - A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia


Total Award Amount

  • 13600.00
  • Direct Costs

  • 10000.00
  • Sponsor Award Id

  • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Xavier   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Investigator